Orum Therapeutics Appoints Chad May as Chief Scientific Officer to Drive Degrader-Antibody Conjugate Innovation and Programs
BOSTON, USA and DAEJEON, South Korea, January 5, 2026 – Orum Therapeutics (Orum or the Company) (KRX: 475830), a biotechnology company pioneering the field of degrader-antibody conjugates (DACs), today announced the appointment of Chad May, Ph.D., as Chief Scientific Officer (CSO). Dr. May brings more than 20 years of oncology and immunology research experience with a track record of advancing antibody drug conjugates (ADCs), T-cell engagers, and other next-generation therapeutic platforms from concept to clinical evaluation.
“Chad has repeatedly demonstrated an ability to take bold scientific concepts and advance them into clinical candidates across multiple therapeutic modalities,” said Sung Joo (SJ) Lee, Ph.D., Founder and CEO of Orum. “His leadership experience in ADCs, T-cell engagers, and structure-driven platform design aligns with Orum’s commitment to precision engineering the next generation of degrader-antibody conjugates. Chad’s expertise strengthens our position as a leader in DAC innovation and supports our progress toward meaningful clinical milestones.”
As CSO, Dr. May will provide scientific vision and R&D leadership, guiding the strategic direction, discovery, and advancement of Orum’s pipeline, including the continued evolution of the Company’s proprietary DAC platforms and programs. He will oversee scientific strategy across discovery, translational research, and preclinical development and will play a central role in shaping the next stage of Orum’s technology innovation and pipeline growth.
“The opportunity to join Orum at this stage of growth is incredibly compelling,” said Dr. May. “The Company’s Dual-Precision Targeted Protein Degradation approach provides a powerful foundation for creating new classes of degraders guided by antibody specificity. I am excited to work closely with the talented scientific and leadership teams to advance Orum’s DAC platforms, expand therapeutic applications across cancer and other serious diseases, and drive the next wave of innovation in degrader-antibody conjugates.”
Dr. May joins Orum from Serotiny, where he served as CSO and oversaw the advancement of a novel gene and cell therapy platform through the company’s post-acquisition integration into Johnson & Johnson. Previously, he served as Senior Vice President of Research and Development at Maverick Therapeutics, where he co-founded and built the R&D organization, advanced multiple conditionally active T-cell engager programs into clinical trials, and led the company’s build-to-buy collaboration with Takeda. Earlier in his career, Dr. May held scientific leadership roles at Pfizer, where he led teams developing T-cell engagers and ADCs and advanced several programs into IND-enabling studies and clinical development. His prior work at ImClone Systems involved the design, conjugation, and evaluation of antibody-based therapeutics. Over his career, Dr. May has built and led high-performing scientific teams, contributed to numerous first-in-class program nominations, and authored more than 30 publications and patents.
About Orum’s TPD²® Approach
Orum’s unique Dual-Precision Targeted Protein Degradation (TPD²®) approach builds novel targeted protein degraders combined with the precise cell delivery mechanisms of antibodies to generate innovative, first-in-class, cell-selective TPDs for the treatment of cancer and other serious diseases. Orum has developed new targeted protein degrader payloads to specifically degrade an intracellular target protein within cancer cells via the E3 ubiquitin ligase pathway. Conjugated to antibodies, the payloads are designed to be delivered specifically to target cells and precisely degrade the intracellular target protein of interest.
About Orum Therapeutics
Orum Therapeutics is a public biotech pioneering the development of cell-specific, targeted protein degraders (TPD²®) with the precision of antibody targeting to develop the next generation of degrader antibody conjugates (DACs) for oncology and beyond. The company is advancing its GSPT1-directed TPD² programs and developing novel degrader payloads to expand the potential of targeted protein degradation. Orum's novel targeted protein degrader payloads are designed to selectively degrade key intracellular proteins, offering a highly targeted approach to treating difficult-to-treat diseases. Orum is located in Lexington, MA, US, and Daejeon, South Korea. For more info, visit www.orumrx.com.
Orum Therapeutics Forward-Looking Statements
This press release contains forward-looking statements that are based on the current expectations and beliefs of Orum Therapeutics, Inc. (“Orum”). Statements in this release regarding matters that are not historical facts, including, but not limited to, statements relating to the development of new classes of degraders; the development of a next generation of degrader-antibody conjugates; the advancement of Orum’s pipeline, including DAC platforms and programs; the expansion of therapeutic applications; the advancement of programs to the clinical stage; and the achievement of clinical milestones are forward-looking statements. These forward-looking statements are based on management’s expectations and assumptions as of the date of this release and are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include, without limitation, the uncertainty of success in research and development activities; competition from alternative therapies; and risks related to the recruitment and retention of key employees, fluctuating markets and economic conditions, and future fundraising. The forward-looking statements in this presentation speak only as of the date of this release, and Orum undertakes no obligation to update or revise any of the statements. Orum cautions investors not to place considerable reliance on the forward-looking statements contained in this release.
Contacts
Corporate: IR/PR, Orum Therapeutics, media@orumrx.com
Media: Jessica Yingling, Ph.D., President, Little Dog Communications Inc., jessica@litldog.com
Orum Therapeutics Secures Approximately US$100 Million to Accelerate Development of Leading Degrader Antibody Conjugate Programs to Treat Serious Diseases
· Funding supports advancing therapeutic programs toward clinical development, expanding discovery across novel payload classes to accelerate next-generation degrader-antibody conjugate (DAC) programs and broadening Orum’s global capabilities and operations
· Participation from leading new investors and renewed commitment from long-time supporters signals strong confidence in Orum’s scientific direction, providing a solid foundation for the company’s next stage of growth and reinforcing Orum’s position as a leader in next-generation DACs
BOSTON & DAEJEON, South Korea, December 18, 2025 – Orum Therapeutics (“Orum” or the “Company”) (KRX: 475830), a public biotechnology company pioneering the field of degrader-antibody conjugates (DACs), today announced that it secured 145 billion KRW (approximately US$100 million) in convertible referred stock investments. This round is led by returning investor KB Investment and includes other existing investors, IMM Investment, Woori Venture Partners and Stassets Investment. New investors include Weiss Asset Management, a Boston-based global investment firm, and Korea Investment Partners, a major institutional venture investor with a strong track record in biotech investment. Additional new investors in this round are DSC Investment, Company K Partners, AON Investment, and DAYLI Partners.
“Our mission is to deliver degrader-antibody conjugate therapeutics that apply powerful degrader payloads with antibody-targeted precision to improve the treatment of cancer and other serious diseases,” said Sung Joo (SJ) Lee, Ph.D., Founder and CEO of Orum. “This investment supports the next stage of our growth as we prepare to advance our next therapeutic programs towards clinical evaluation, develop additional novel payloads, and continue to build platforms that can generate differentiated drug candidates across oncology and beyond. We appreciate the confidence of both new and existing investors who share our commitment to delivering meaningful innovation for patients.”
This investment supports the advancement of ORM-1153 and additional programs in Orum’s pipeline and continued refinement of the Company’s DAC platforms, including development of additional novel payload classes beyond GSPT1. It also supports the expansion of Orum’s scientific and operational infrastructure as the Company advances additional targeted DAC programs based on principles of selectivity, potency, and rational payload design. These efforts are foundational to Orum’s strategy to generate differentiated therapeutic DAC programs for oncology and other serious diseases.
About Orum’s TPD²® Approach
Orum’s unique Dual-Precision Targeted Protein Degradation (TPD²®) approach builds novel targeted protein degraders combined with the precise cell delivery mechanisms of antibodies to generate innovative, first-in-class, cell-selective TPDs for the treatment of cancer and other serious diseases. Orum has developed new targeted protein degrader payloads to specifically degrade an intracellular target protein within cancer cells via the E3 ubiquitin ligase pathway. Conjugated to antibodies, the payloads are designed to be delivered specifically to target cells and precisely degrade the intracellular target protein of interest.
About Orum Therapeutics
Orum Therapeutics is a public biotech pioneering the development of cell-specific, targeted protein degraders (TPD²®) with the precision of antibody targeting to develop the next generation of degrader antibody conjugates (DACs) for oncology and beyond. The company is advancing its GSPT1-directed TPD² programs and developing novel degrader payloads to expand the potential of targeted protein degradation. Orum’s novel targeted protein degrader payloads are designed to selectively degrade key intracellular proteins, offering a highly targeted approach to treating difficult-to-treat diseases. Orum is located in Lexington, MA, US, and Daejeon, South Korea. For more info, visit www.orumrx.com.
About KB Investment Co.
KB Investment Co., Ltd. (KBI) is a global venture capital firm backed by KB Financial Group (KRX: 105560, NYSE: KB), Korea’s largest and most influential financial institution. Since its establishment in 1990, KBI has invested across early- to growth-stage companies, building a diversified portfolio of more than 500 companies spanning biotechnology, healthcare, and industrial innovation. KBI supports companies driven by strong science and advanced technologies to address critical needs across patients, businesses, and society. Through its Boston office, KBI operates a global investment platform that connects leading U.S. innovation hubs with Korea and the broader Asian market. With a growing international presence and a proven track record of supporting globally scalable companies, KBI remains committed to empowering entrepreneurs and advancing long-term value creation. For more information, visit www.kbic.co.kr.
Orum Therapeutics Forward-Looking Statements
This press release contains forward-looking statements that are based on the current expectations and beliefs of Orum Therapeutics, Inc. (“Orum”). Statements in this release regarding matters that are not historical facts, including, but not limited to, statements relating to the expansion of Orum’s scientific and operational infrastructure, the advancement of programs beyond the preclinical stage, the translation of positive preclinical results to the clinic, the development of new platforms and next-generation degraders and other payloads, the acceleration of next-generation programs, the types of diseases for which Orum’s products might serve as a therapeutic option, and the sufficiency of funding proceeds to allow achievement of goals are forward-looking statements. These forward-looking statements are based on management’s expectations and assumptions as of the date of this release and are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include, without limitation, the uncertainty of success in research and development activities; competition from alternative therapies; and risks related to the recruitment and retention of key employees, fluctuating markets and economic conditions, and future fundraising. The forward-looking statements in this presentation speak only as of the date of this release, and Orum undertakes no obligation to update or revise any of the statements. Orum cautions investors not to place considerable reliance on the forward-looking statements contained in this release.
Contacts
Corporate: IR/PR, Orum Therapeutics, media@orumrx.com
Media: Jessica Yingling, Ph.D., President, Little Dog Communications Inc., jessica@litldog.com
Orum Therapeutics Presents Preclinical Data at ASH 2025 Demonstrating Potent and Selective Antitumor Activity of ORM-1153, a CD123-Targeting Degrader Antibody Conjugate for Acute Myeloid Leukemia
BOSTON & DAEJEON, South Korea, December 8, 2025 – Orum Therapeutics (“Orum” or the “Company”) (KRX: 475830), a public biotechnology company pioneering the field of degrader-antibody conjugates (DACs), today announced the presentation of preclinical data for ORM-1153 at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6 to 9, 2025, in Orlando, Florida. ORM-1153 is a novel CD123-targeting DAC designed to deliver Orum’s proprietary GSPT1-degrading payload selectively into cancer cells to achieve targeted protein degradation and antitumor activity in acute myeloid leukemia (AML) and other CD123-positive hematological malignancies.
“These data highlight ORM-1153 as a differentiated therapeutic candidate designed to address the need for more effective and better-tolerated treatments for acute myeloid leukemia,” said Sung Joo (SJ) Lee, Ph.D., Founder and CEO of Orum Therapeutics. “AML remains one of the most challenging hematologic cancers to treat, with frequent relapse and limited options, particularly for patients with TP53-mutant disease. These data demonstrate the potential of ORM-1153 to achieve potent antitumor activity with a differentiated safety profile, addressing long-standing limitations of current AML therapies and further validating the versatility of our targeted protein degrader approach.”
The preclinical data presented at ASH show that ORM-1153 drives efficient, CD123-dependent internalization and degradation of GSPT1, resulting in strong and durable antitumor activity in AML models, including TP53-mutant disease. In comparative studies, ORM-1153 demonstrated approximately 1,000-fold higher potency than the unconjugated degrader payload and produced dose-dependent tumor regression in a disseminated AML xenograft model, with complete and durable responses at the highest dose level.
Importantly, ORM-1153 maintained a favorable tolerability profile and showed minimal effects on normal hematopoietic progenitors in colony-forming assays, suggesting potential for a differentiated therapeutic window compared with current standard-of-care. Together, these findings support ORM-1153 as a promising candidate for the treatment of AML and other CD123-positive hematologic malignancies.
About Orum’s TPD²® Approach
Orum’s unique Dual-Precision Targeted Protein Degradation (TPD²®) approach builds novel targeted protein degraders combined with the precise cell delivery mechanisms of antibodies to generate innovative, first-in-class, cell-selective TPDs for the treatment of cancer and other serious diseases. Orum has developed new targeted protein degrader payloads to specifically degrade an intracellular target protein within cancer cells via the E3 ubiquitin ligase pathway. Conjugated to antibodies, the payloads are designed to be delivered specifically to target cells and precisely degrade the intracellular target protein of interest.
About Orum Therapeutics
Orum Therapeutics is a public biotech pioneering the development of cell-specific, targeted protein degraders (TPD²®) with the precision of antibody targeting to develop the next generation of degrader antibody conjugates (DACs) for oncology and beyond. The company is advancing its GSPT1-directed TPD² programs and developing novel degrader payloads to expand the potential of targeted protein degradation. Orum's novel targeted protein degrader payloads are designed to selectively degrade key intracellular proteins, offering a highly targeted approach to treating difficult-to-treat diseases. Orum is located in Lexington, MA, US, and Daejeon, South Korea. For more info, visit www.orumrx.com.
Orum Therapeutics Forward-Looking Statements
This press release contains forward-looking statements that are based on the current expectations and beliefs of Orum Therapeutics, Inc. (“Orum”). Statements in this release regarding matters that are not historical facts, including, but not limited to, statements relating to the potential potency, tolerability, therapeutic window, and durable activity of ORM-1153; its advancement beyond the preclinical stage; its potential indications; and the potential versatility of Orum’s targeted protein degrader approach are forward-looking statements. These forward-looking statements are based on management’s expectations and assumptions as of the date of this release and are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include, without limitation, the uncertainty of success in research and development activities; competition from alternative therapies; and risks related to the recruitment and retention of key employees, fluctuating markets and economic conditions, and future fundraising. The forward-looking statements in this presentation speak only as of the date of this release, and Orum undertakes no obligation to update or revise any of the statements. Orum cautions investors not to place considerable reliance on the forward-looking statements contained in this release.
Contacts
Corporate: IR/PR, Orum Therapeutics, media@orumrx.com
Media: Jessica Yingling, Ph.D., President, Little Dog Communications Inc., jessica@litldog.com
Orum Therapeutics Announces Presentation of Preclinical Data for ORM-1153 at the 2025 American Society of Hematology (ASH) Annual Meeting
BOSTON & DAEJEON, South Korea, November 3, 2025 – Orum Therapeutics (“Orum” or the “Company”) (KRX: 475830), a public biotechnology company pioneering the field of degrader-antibody conjugates (DACs), today announced that preclinical data for ORM-1153, a CD123-targeting DAC with a GSPT1-degrading payload, have been selected for presentation at the upcoming 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6 to 9, 2025, in Orlando, Florida.
The presentation will feature data from preclinical studies of ORM-1153, a novel CD123-targeting DAC designed to deliver Orum’s proprietary GSPT1-degrading payload, SMol006, selectively into cancer cells to achieve targeted protein degradation and antitumor activity in acute myeloid leukemia (AML). The results support further investigation of ORM-1153 as a potential therapeutic option for AML and other CD123-positive hematologic malignancies, including those with TP53-mutant status.
Details of the ASH 2025 Presentation
Title: ORM-1153: A CD123-Targeting Degrader Antibody Conjugate with GSPT1-Degrading Payload Exhibits Potent Preclinical Antitumor Activity in Acute Myeloid Leukemia
Session: 604. Molecular Pharmacology and Drug Resistance: Myeloid Neoplasms: Poster III
Session Type: Poster Presentation
Session Date and Time: December 8, 2025, from 6 pm to 8 pm ET
Location: Orange County Convention Center (OCCC), West Halls B3-B4
Abstract Number: 5051
About Orum’s TPD²® Approach
Orum’s unique Dual-Precision Targeted Protein Degradation (TPD²®) approach builds novel targeted protein degraders combined with the precise cell delivery mechanisms of antibodies to generate innovative, first-in-class, cell-selective TPDs for the treatment of cancer and other serious diseases. Orum has developed new targeted protein degrader payloads to specifically degrade an intracellular target protein within cancer cells via the E3 ubiquitin ligase pathway. Conjugated to antibodies, the payloads are designed to be delivered specifically to target cells and precisely degrade the intracellular target protein of interest.
About Orum Therapeutics
Orum Therapeutics is a public biotech pioneering the development of cell-specific, targeted protein degraders (TPD²®) with the precision of antibody targeting to develop the next generation of degrader antibody conjugates (DACs) for oncology and beyond. The company is advancing its GSPT1-directed TPD² programs and developing novel degrader payloads to expand the potential of targeted protein degradation. Orum's novel targeted protein degrader payloads are designed to selectively degrade key intracellular proteins, offering a highly targeted approach to treating difficult-to-treat diseases. Orum is located in Lexington, MA, US, and Daejeon, South Korea. For more info, visit www.orumrx.com.
Orum Therapeutics Forward-Looking Statements
This press release contains forward-looking statements that are based on the current expectations and beliefs of Orum Therapeutics, Inc. (“Orum”). Statements in this release regarding matters that are not historical facts, including, but not limited to, statements relating to the potential for ORM-1153 to advance beyond the preclinical stage and the types of malignancies for which it might serve as a therapeutic option are forward-looking statements. These forward-looking statements are based on management’s expectations and assumptions as of the date of this release and are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include, without limitation, the uncertainty of success in research and development activities; competition from alternative therapies; and risks related to the recruitment and retention of key employees, fluctuating markets and economic conditions, and future fundraising. The forward-looking statements in this presentation speak only as of the date of this release, and Orum undertakes no obligation to update or revise any of the statements. Orum cautions investors not to place considerable reliance on the forward-looking statements contained in this release.
Contacts
Corporate: IR/PR, Orum Therapeutics, media@orumrx.com
Media: Jessica Yingling, Ph.D., President, Little Dog Communications Inc., jessica@litldog.com
Orum Therapeutics Appoints Dr. Dorin Toader as Head of Platform Technology to Advance Orum’s Degrader–Antibody Conjugate Payload Platforms and Expand TPD²® Therapeutic Applications
BOSTON, USA & DAEJEON, South Korea, October 15, 2025 – Orum Therapeutics (“Orum” or the “Company”) (KRX: 475830), a public biotechnology company pioneering the field of degrader-antibody conjugates (DACs), today announced the appointment of Dorin Toader, Ph.D., as Head of Platform Technology. Dr. Toader brings more than 27 years of experience in drug discovery, including over 15 years in antibody-drug conjugates (ADCs). He will be responsible for defining and executing Orum’s technology vision, leading efforts across chemistry and antibody engineering, guiding innovation in payload design, conjugation technologies, linker–payload strategies, structural biology, and computational modeling to advance Orum’s Dual-Precision Targeted Protein Degradation (TPD²) approach and expand its therapeutic applications.
“Dorin’s career reflects a proven ability to translate bold science into clinical candidates, including advancing multiple first-in-class ADC candidates into the clinic,” said Sung Joo (SJ) Lee, Founder and CEO of Orum. “His deep expertise in payload and linker design, together with Orum’s established capabilities in structure-based drug design and advanced computational methods such as physics-based modeling and machine learning, will strengthen our ability to innovate and scale our platforms. These combined strengths position us to build the next generation of targeted degrader-antibody conjugates with the potential to benefit patients across a broad range of cancers and other serious diseases.”
“The field of protein degradation is entering a transformative stage, and Orum is at the forefront with its proprietary Dual-Precision Targeted Protein Degradation approach,” said Dr. Toader. “I was drawn to Orum’s vision of creating entirely new classes of targeted degraders by uniting them with the precision of antibody delivery and its investment in structure-based design and computational innovation to drive DAC research and development. I look forward to applying my experience in payload and bioconjugation chemistry to expand Orum’s DAC platforms and broaden the impact of degrader-based medicines in the clinic.”
Dr. Toader joins Orum from Mersana Therapeutics, where he most recently served as Vice President of Chemistry and Bioconjugation, leading teams that delivered novel payload platforms and advanced pipeline programs, including the first STING agonist ADC candidate into clinical development. Earlier in his career, he held scientific and leadership roles at MedImmune, AstraZeneca, and Zeneca Pharmaceuticals, where he contributed to multiple first-in-class drug candidate nominations and investigational new drug (IND) applications. Over his 23-year career in oncology drug discovery, Dr. Toader has built and led high-performing cross-functional teams, authored more than 40 peer-reviewed publications, and is a named inventor on six granted patents.
About Orum’s TPD²® Approach
Orum’s unique Dual-Precision Targeted Protein Degradation (TPD²®) approach builds novel targeted protein degraders combined with the precise cell delivery mechanisms of antibodies to generate innovative, first-in-class, cell-selective TPDs for the treatment of cancer and other serious diseases. Orum has developed new targeted protein degrader payloads to specifically degrade an intracellular target protein within cancer cells via the E3 ubiquitin ligase pathway. Conjugated to antibodies, the payloads are designed to be delivered specifically to target cells and precisely degrade the intracellular target protein of interest.
About Orum Therapeutics
Orum Therapeutics is a public biotech pioneering the development of cell-specific, targeted protein degraders (TPD²®) with the precision of antibody targeting to develop the next generation of degrader antibody conjugates (DACs) for oncology and beyond. The company is advancing its GSPT1-directed TPD² programs and developing novel degrader payloads to expand the potential of targeted protein degradation. Orum's novel targeted protein degrader payloads are designed to selectively degrade key intracellular proteins, offering a highly targeted approach to treating difficult-to-treat diseases. Orum is located in Lexington, MA, US, and Daejeon, South Korea. For more info, visit www.orumrx.com.
Orum Therapeutics Forward-Looking Statements
This press release contains forward-looking statements that are based on the current expectations and beliefs of Orum Therapeutics, Inc. (“Orum”). Statements in this release regarding matters that are not historical facts, including, but not limited to, statements relating to the expansion and scaling of its platforms; the creation of next-generation targeted degrader-antibody conjugates; the potential initiation of clinical trials; and the range of indications for Orum’s products and their potential benefit to patients are forward-looking statements. These forward-looking statements are based on management’s expectations and assumptions as of the date of this release and are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include, without limitation, the uncertainty of success in research and development activities; competition from alternative therapies; and risks related to the recruitment and retention of key employees, fluctuating markets and economic conditions, and future fundraising. The forward-looking statements in this presentation speak only as of the date of this release, and Orum undertakes no obligation to update or revise any of the statements. Orum cautions investors not to place considerable reliance on the forward-looking statements contained in this release.
Contacts
Corporate: IR/PR, Orum Therapeutics, media@orumrx.com, +82-10-7351-3031
Media: Jessica Yingling, Ph.D., President, Little Dog Communications Inc., jessica@litldog.com